On July 13, Gilead Sciences rose 3.2% overnight, trading at $133.99/share with turnover of $434,200, rebounding notably from a period of consecutive pullbacks.

On the news front, HSBC recently upgraded Gilead Sciences from Hold to Buy and raised its target price significantly from $133 to $155, providing strong support for the stock. According to FactSet-polled analysts, the stock carries an average Buy rating with a mean price target of $160.74. Additionally, Gilead's core oncology product Trodelvy received FDA approval in late June for first-line treatment of advanced triple-negative breast cancer, available as monotherapy or in combination with Merck's Keytruda. The NCCN has designated it as a category 1 preferred treatment option regardless of PD-L1 status, opening new growth potential for the company's oncology segment.

The stock had previously declined 3.04% on July 10 amid broad weakness across the biotech sector. The current rebound appears to reflect the market re-pricing fundamental catalysts including the analyst upgrade and the expanded Trodelvy indication.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)